インスリン治療を受けている2型糖尿病患者における経口セマグルチドとプラセボの有効性および安全性

基本情報

NCT ID

NCT03021187

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

731

治験依頼者名

Novo Nordisk A/S

概要

This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of oral semaglutide versus placebo in subjects with Type 2 Diabetes Mellitus treated with insulin. All subjects should continue their pre-trial insulin therapy (basal, basal-bolus or premixed regimen including combinations of soluble insulins) throughout the trial. Subjects treated with metformin in addition to insulin treatment must continue their metformin treatment throughout the entire trial.

対象疾患

介入

依頼者（Sponsor）